Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GMM-2 is a combination pharmaceutical drug indicated for the treatment of type 2 diabetes mellitus. It comprises two active ingredients: Glimepiride and Metformin. Glimepiride, a sulfonylurea, acts by stimulating the beta cells in the pancreas to produce and release more insulin, thereby lowering blood sugar levels. Metformin, a biguanide, works through multiple mechanisms, including reducing glucose production by the liver, delaying glucose absorption from the intestines, and increasing the sensitivity of muscle cells to insulin, which allows for more effective glucose uptake from the blood. This dual-action approach aims to improve glycemic control in adult patients whose blood sugar levels are not adequately managed by diet and exercise alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GMM-2.